source
- Enveda Biosciences raises $311 million in Series E to accelerate nature-derived drug developmentEnveda Biosciences announced a $311 million Series E financing round, adding to the more than $500 million it has raised in previous rounds. The new capital follows a $130 million Series C in Nove…
- FDA advisory panel backs Grail's Galleri multi-cancer blood test, citing benefits outweigh risksThe Food and Drug Administration’s advisory committee voted to endorse Galleri, a blood test from Grail that screens for multiple cancers, saying the benefits outweigh the risks. The panel’s vote…